ONCODESIGN announced a service partnership with Galderma. The primary aim of this multi-year service agreement is to design and discover new skincare drug candidates, through close cooperation with Galderma’s own research teams, leveraging Oncodesign’s ability to validate the therapeutic potential of new molecular targets of interest to Galderma. The agreement is the first Integrated Drug Discovery Services contract to be sealed by Oncodesign after it introduced its new commercial offering focused on formulating and selecting new drug candidates. This collaboration has been established to validate new therapeutic targets and to generate new skincare drug candidates.